FIBROGEN INC (FGEN) Stock Analyst Ratings
USA - NASDAQ:FGEN - US31572Q8814 - Common Stock
9.2701 USD
-0.67 (-6.74%)
ChartMill assigns a Buy % Consensus number of 80% to FGEN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 43.86. This target is 373.13% above the current price.
FGEN was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about FGEN.
In the previous month the buy percentage consensus was at a similar level.
FGEN was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-08 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2023-06-27 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-06-27 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-06-26 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-06-26 | Stifel | Downgrade | Buy -> Hold |
| 2023-06-26 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-06-26 | B of A Securities | Downgrade | Buy -> Neutral |
| 2023-06-02 | Stifel | Upgrade | Hold -> Buy |
| 2023-02-28 | Cowen & Co. | Maintains | Market Perform |
| 2023-02-23 | Goldman Sachs | Maintains | Sell |
| 2023-02-21 | Goldman Sachs | Maintains | Sell |
| 2023-01-31 | William Blair | Upgrade | Market Perform -> Outperform |
| 2023-01-26 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2023-01-05 | B of A Securities | Upgrade | Neutral -> Buy |
| 2022-11-08 | Goldman Sachs | Maintains | Sell |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-03-01 | Goldman Sachs | Maintains | Sell |
| 2021-09-22 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2021-08-20 | Raymond James | Upgrade | Underperform -> Market Perform |
| 2021-08-10 | SVB Leerink | Maintains | Outperform |
| 2021-07-16 | Stifel | Downgrade | Buy -> Hold |
| 2021-07-16 | B of A Securities | Downgrade | Buy -> Neutral |
| 2021-04-07 | Mizuho | Downgrade | Buy -> Neutral |
| 2021-04-07 | SVB Leerink | Maintains | Outperform |
| 2021-04-07 | JP Morgan | Upgrade | Underweight -> Neutral |
FIBROGEN INC / FGEN FAQ
What is the average price target for FIBROGEN INC (FGEN) stock?
8 analysts have analysed FGEN and the average price target is 43.86 USD. This implies a price increase of 373.13% is expected in the next year compared to the current price of 9.2701.
How do analysts rate FIBROGEN INC (FGEN)?
The consensus rating for FIBROGEN INC (FGEN) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.